{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-036112","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.559125+00:00","generated_at":"2026-06-15T21:19:37.703980+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protara reports Q1 net loss $9.0M; plans Phase 2 trials for TARA-002 in NMIBC and LMs","bullets":["Cash, equivalents and restricted cash $89.5M at March 31, 2023; funding expected into 2025.","Net loss $9.0M ($0.80/sh) vs $10.8M ($0.96) in Q1 2022; R&D $5.1M, G&A $4.6M.","Positive preliminary data: TARA-002 well tolerated; tumor regression in all 3 evaluable CIS patients, including a CR in a BCG-unresponsive patient.","ADVANCED-2 Phase 1b/2 trial in up to 102 CIS patients planned for 2H23; STARBORN-1 Phase 2 in pediatric LMs cleared by FDA, start Q4 2023.","IV Choline Chloride IFALD prospective study ongoing; results expected Q3 2023, then regulatory feedback."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-036112","json":"https://secwatch.observer/filing/0001213900-23-036112.json","markdown":"https://secwatch.observer/filing/0001213900-23-036112.md","text":"https://secwatch.observer/filing/0001213900-23-036112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023036112/0001213900-23-036112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023036112/ea177795-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:19:37.703980+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2c75ca4cb5c1deeef23dcdd9dc9ee09f1d000c17","claim":"Protara Therapeutics, Inc. reported first quarter ended March 31, 2023 results: net income a net loss of $9.0 million, EPS $0.80 per share.","evidence_excerpt":"For the first quarter of 2023, Protara reported a net loss of $9.0 million, or $0.80 per share, compared with a net loss of $10.8 million, or $0.96 per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023036112/0001213900-23-036112-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"a net loss of $9.0 million"},{"label":"EPS","value":"$0.80 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}